Drugs / LY3884961
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05487599 | Dec 2022 → Aug 2032 expected | Gaucher disease type I | Prevail Therapeutics | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04411654 | Jun 2021 → May 2028 expected | Gaucher disease type II | Prevail Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04127578 | Jan 2020 → Mar 2031 expected | Parkinson disease | Prevail Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3884961 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04411654 ↗ |
| Known as | PR001 | “A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)” NCT05487599 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “LY3884961 is a replication-incompetent recombinant adeno-associated virus (AAV) vector.” NCT05487599 ↗ |
| Route | Other | “administered intra-cisterna magna” NCT04127578 ↗ |